Abacavir ( DrugBank: Abacavir )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2
135	アイカルディ症候群	1
265	脂肪萎縮症	9
325	遺伝性自己炎症疾患	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05193994 (ClinicalTrials.gov)	February 24, 2022	6/12/2021	Triumeq in Amyotrophic Lateral Sclerosis	Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Dolutegravir, Abacavir and Lamivudine;Drug: Placebo	Macquarie University, Australia	King's College London;Stichting TRICALS Foundation	Recruiting	18 Years	N/A	All	390	Phase 3	Australia
2	EUCTR2020-005069-15-NL (EUCTR)	23/06/2021	14/04/2021	LIGHTHOUSE 2	RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - Lighthouse 2	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Triumeq Product Name: Triumeq INN or Proposed INN: Dolutegravir INN or Proposed INN: Abacavir INN or Proposed INN: Lamivudine	Stichting TRICALS Foundation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	390	Phase 3	Australia;Netherlands;United Kingdom

135. アイカルディ症候群

臨床試験数 : 1 / 薬物数 : 9 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-002710-23-FR (EUCTR)		18/06/2015	N/A	N/A - AGS	MedDRA version: 18.0;Level: PT;Classification code 10054935;Term: Aicardi's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Zidovudine Product Name: Zidovudine Product Code: J05A F01 INN or Proposed INN: Zidovudine Other descriptive name: retrovir Trade Name: lamivudine Product Name: lamivudine Product Code: GX CJ7 INN or Proposed INN: lamivudine Other descriptive name: epivir Trade Name: Abacavir Product Name: Abacavir Product Code: GX 623 INN or Proposed INN: abacavir Other descriptive name: ziagen	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	France

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04904406 (ClinicalTrials.gov)	October 22, 2020	9/10/2020	Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals	Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1	Hiv;HIV Infections;HIV Cardiomyopathy;Weight Change, Body;HIV Lipodystrophy;Cardiovascular Diseases	Drug: Dolutegravir / Lamivudine Oral Tablet	Thomas Benfield	NULL	Recruiting	18 Years	N/A	All	95	Phase 4	Denmark
2	NCT00865007 (ClinicalTrials.gov)	December 2008	18/3/2009	Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy	A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir	HIV Infection;Lipodystrophy;HIV Infections	Drug: Monotherapy (Lopinavir/ritonavir);Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TC	Fundacion SEIMC-GESIDA	Abbott	Completed	18 Years	N/A	Both	88	Phase 4	Spain
3	NCT00426296 (ClinicalTrials.gov)	August 2006	23/1/2007	SHARE: Simple HAART With Abacavir, Reyataz, and Epivir	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	HIV Infections;Lipodystrophy	Drug: atazanavir (Reyataz);Drug: ritonavir (Norvir)	Clinical Alliance for Research & Education - Infectious Diseases, LLC.	GlaxoSmithKline	Recruiting	18 Years	N/A	Both		Phase 4	United States
4	NCT00139178 (ClinicalTrials.gov)	March 2004	30/8/2005	Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.	Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities	HIV Associated Lipodystrophy Syndrome.;HIV;Hypercholesterolemia;Lipoatrophy	Drug: Different HAART regimens	Danish HIV Research Group	Odense University Hospital;Rigshospitalet, Denmark;Hvidovre University Hospital;Aarhus University Hospital	Completed	18 Years	N/A	Both	100	Phase 4	Denmark
5	NCT00647946 (ClinicalTrials.gov)	February 2003	27/3/2008	Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue	A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART)	Lipodystrophy	Drug: tenofovir DF;Drug: abacavir 300mg twice daily	Gilead Sciences	NULL	Completed	18 Years	N/A	Both	100	Phase 2	United Kingdom
6	NCT00192660 (ClinicalTrials.gov)	February 2003	12/9/2005	HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)	Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time	HIV-Associated Lipodystrophy Syndrome;Cardiovascular Disease	Drug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)	Kirby Institute	St Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	N/A	Both	80	Phase 4	Australia
7	NCT00028314 (ClinicalTrials.gov)	March 2002	20/12/2001	Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients	A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting	HIV Infections;Lipodystrophy;Wasting Disease	Drug: Abacavir sulfate;Drug: Atazanavir/Ritonavir;Drug: Lopinavir/Ritonavir;Drug: Nevirapine	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	13 Years	N/A	Both	150	N/A	United States
8	NCT00021463 (ClinicalTrials.gov)	April 2001	14/7/2001	Changing to Nonprotease Inhibitor Treatment to Improve Side Effects	Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities	HIV Infections;Lipodystrophy	Drug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: Nevirapine	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	13 Years	N/A	Both	342	Phase 2	United States
9	NCT00005764 (ClinicalTrials.gov)	May 2000	30/5/2000	A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients	Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)	HIV Infections;Lipodystrophy	Drug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: Lamivudine	Glaxo Wellcome	NULL	Completed	18 Years	N/A	Both	100	Phase 4	United States

先頭へ

325. 遺伝性自己炎症疾患

臨床試験数 : 5 / 薬物数 : 11 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02363452 (ClinicalTrials.gov)	September 10, 2015	15/1/2015	Reverse Transcriptase Inhibitors in AGS	A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)	Aicardi-Goutières Syndrome (AGS)	Drug: Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir	Assistance Publique - Hôpitaux de Paris	NULL	Completed	1 Month	17 Years	All	11	Phase 2	France

先頭へ